Page 22 - GB-RI-PierreFabre-Complet-INTERACTIF

20 INTEGRATED ANNUAL REPORT 2021 - PIERRE FABRE Major advances in the five pillars of transformation In order to achieve profitable growth, the Group has identified five strategic priorities for its Transformation Plan. 2020 saw a number of major advances, including consolidation of its unique position based on an alliance of medical and naturalness, the introduction of a new organizational structure, and the refocusing of the Group's activities on oncology, dermatology and dermo-cosmetics. Taking advantage of our unique positioning The Group has reaffirmed the characteristics that have set the company apart since its creation: an alliance of medical expertise and naturalness for the benefit of humankind. This positioning is built on our renowned, complementary expertise in life sciences: cellular biology, biotechnology, botany, and biodiversity. Our achievements in 2020 include: • Roll-out of Conscious Care: this strategy was launched by our Dermo-Cosmetics & Personal Care Business Unit and is based on four specific commitments designed to encourage virtuous and sustainable dermo-cosmetics with the goal of influencing product design (formulation, packaging, manufacture, etc.). (read more on p. 27) • Carbon assessment and definition of the Group’s climate strategy: in line with the 2015 Paris Agreement’s goal to limit global warming to 2°C, the Group is aiming for a 33% reduction in its CO2 emissions by 2030 and a contribution to carbon neutrality by 2050. • Partnership agreement with Peking University in China to develop new medical devices or medicines for the Chinese market. 5 (read more on p. 45) patents filed for new plant-based active ingredients in 2020 René Furterer rooting for Ivive, a 100% plant-based dye Ivive, launched by the René Furterer brand, is a new 100% plant-based professional hair color range with organic and vegan certification. Our Gaillac site employs an exclusive and patented extraction process for obtaining only the active part of the plant, free from any cellulose, fibers, or heavy metals. Available since June 2021, Ivive in particular targets professional hairdressers prone to eczema of the hands, as well as certain consumer and patient groups: cancer patients, people with scalp problems, pregnant and breastfeeding women etc. The launch and promotion of Ivive have been accompanied by a medical value campaign based on an in-use test and a study of the prevalence of hand eczema among professional hairdressers as well as clinical studies of patients and consumers. January Roll-out of the new organizational structure, creation of the Patients & Consumers Medical Department June European marketing authorization for a new BRAF+ colorectal cancer treatment July Sale of our Virrey del Pino specialist pharmaceutical production site in Argentina and medical packaging plant in Vietnam. October Sale of the Galénic and Elancyl brands, launch of a clinical trial for a new monoclonal antibody developed by Pierre Fabre targeting the VISTA immune checkpoint in patients with solid tumors. November Partnership with the South Korean biotech Y-Biologics for the development of new immune therapies using monoclonal antibodies. December Partnership with the EspeRare Foundation for the development of a first treatment for XLHED, incorporation of CSR criteria into Pierre Fabre syndicated loans.